The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 10, 2011, Pages 7400-7405

  Fontaine, Olivier ^a,b   Olivier, Sébastien ^a   Descovich, Denise ^a   Cordahi, Ghassan ^a   Vaucher, Elvire ^a   Lesk, Mark R ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CLINICAL TRIAL; EXUDATIVE MACULAR DEGENERATION; FEMALE; HUMAN; LASER DOPPLER FLOWMETRY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA BLOOD FLOW; RETINA BLOOD VESSEL; TISSUE PERFUSION; VISUAL ACUITY; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CIRCULATION; DRUG ANTAGONISM; DRUG EFFECT; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINA ARTERY; VASCULAR SMOOTH MUSCLE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD CIRCULATION; BLOOD FLOW VELOCITY; BLOOD PRESSURE; HUMANS; INTRAVITREAL INJECTIONS; LASER-DOPPLER FLOWMETRY; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PROSPECTIVE STUDIES; RETINA; RETINAL ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84856369109     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6646     Document Type: Article

References (36)

1. Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Adv Drug Deliv Rev. 2005;57:1994-2009.
2. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am. 2006;19:335-344.
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
4. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2006;113:2002. e1-2002. e12.
5. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
6. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247:1-11.
7. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695. e1-1695. e15.
8. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
9. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina. 2006;26:495-511.
10. Michel JB. Role of endothelial nitric oxide in the regulation of the vasomotor system [in French]. Pathol Biol (Paris). 1998;46:181-189.
11. Brylla E, Tscheudschilsuren G, Santos AN, Nieber K, Spanel-Borowski K, Aust G. Differences between retinal and choroidal microvascular endothelial cells (MVECs) under normal and hypoxic conditions. Exp Eye Res. 2003;77:527-535.
12. Garcia Jr JP, Garcia PT, Rosen RB. Retinal blood flow in the normal human eye using the canon laser blood flowmeter. Ophthalmic Res. 2002;34:295-299.
13. Yoshida A, Feke GT, Mori F, et al. Reproducibility and clinical application of a newly developed stabilized retinal laser Doppler instrument. Am J Ophthalmol. 2003;135:356-361.
14. Michelson G, Welzenbach J, Pal I, Harazny J. Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol. 1998;82:1294-1300.
15. Michelson G, Welzenbach J, Pal I, Harazny J. Functional imaging of the retinal microvasculature by scanning laser Doppler flowmetry. Int Ophthalmol. 2001;23:327-335.
16. Hafez AS, Bizzarro RL, Rivard M, Lesk MR. Changes in optic nerve head blood flow after therapeutic intraocular pressure reduction in glaucoma patients and ocular hypertensives. Ophthalmology. 2003;110:201-210.
17. Hafez AS, Bizzarro RL, Rivard M, et al. Reproducibility of retinal and optic nerve head perfusion measurements using scanning laser Doppler flowmetry. Ophthalmic Surg Lasers Imaging. 2003;34: 422-432.
18. Bonnin P, Pournaras JA, Lazrak Z, et al. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin®) in neovascular age-related macular degeneration. Acta Ophthalmol. 2010;88:641-645.
19. Sugimoto H, Kaneko T, Hirota M, Inoue S, Takeda S, Nakao A. Physical hemodynamic interaction between portal venous and hepatic arterial blood flow in humans. Liver Int. 2005;25:282-287.
20. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2008;86:365-371.
21. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1755-1761.
22. Guan K, Hudson C, Flanagan JG. Variability and repeatability of retinal blood flow measurements using the Canon Laser Blood Flowmeter. Microvasc Res. 2003;65:145-151.
23. Milbocker MT, Feke GT, Goger DG. Laser Doppler velocimetry stabilized in one dimension. IEEE Trans Biomed Eng. 1991;38: 928-930.
24. Ozdemir M, Temizdemir H. Age-and gender-related tear function changes in normal population. Eye (Lond). 2010;24:79-83.
25. Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol. 2009;16:15-21.
26. Hosking SL, Embleton S, Kagemann L, Chabra A, Jonescu-Cuypers C, Harris A. Detector sensitivity influences blood flow sampling in scanning laser Doppler flowmetry. Graefes Arch Clin Exp Ophthalmol. 2001;239:407-410.
27. Kagemann L, Harris A, Chung HS, Evans D, Buck S, Martin B. Heidelberg retinal flowmetry: factors affecting blood flow measurement. Br J Ophthalmol. 1998;82:131-136.
28. Tsang AC, Harris A, Kagemann L, Chung HS, Snook BM, Garzozi HJ. Brightness alters Heidelberg retinal flowmeter measurements in an in vitro model. Invest Ophthalmol Vis Sci. 1999;40:795-799.
29. Hayreh SS. Evaluation of optic nerve head circulation: review of the methods used. J Glaucoma. 1997;6:319-330.
30. Meyer P, Champion C, Schlotzer-Schrehardt U, Flammer J, Haefliger IO. Localization of nitric oxide synthase isoforms in porcine ocular tissues. Curr Eye Res. 1999;18:375-380.
31. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298(part 2):249-258.
32. Chakravarthy U, Stitt AW, McNally J, Bailie JR, Hoey EM, Duprex P. Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. Curr Eye Res. 1995;14: 285-294.
33. D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol. 2007;171:14-18.
34. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One. 2008;3:e3554.
35. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci. 2006;26:12439-12446.
36. Medeiros NE, Curcio CA. Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42:795-803.